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International Collaboration Provides Convincing Linkage Replication
in Complex Disease through Analysis of a Large Pooled Data Set:
Crohn Disease and Chromosome 16
The IBD International Genetics Consortium*
Numerous familial, non-Mendelian (i.e., complex) diseases have been screened by linkage analysis for regions
harboring susceptibility genes. Except for rare, high-penetrance syndromes showing Mendelian inheritance, such
as BRCA1 and BRCA2, most attempts have failed to produce replicable linkage findings. For example, in multiple
sclerosis and other complex diseases, there have been many reports of significant linkage, followed by numerous
failures to replicate. In inflammatory bowel disease (IBD), linkage to two regions has elsewhere been reported at
genomewide significance levels: the pericentromeric region on chromosome 16 (IBD1) and chromosome 12q (IBD2).
As with other complex diseases, the subsequent support for these localizations has been variable. In this article,
we report the results of an international collaborative effort to investigate these putative localization by pooling
of data sets that do not individually provide convincing evidence for linkage to these regions. Our results, generated
by the genotyping and analysis of 12 microsatellite markers in 613 families, provide unequivocal replication of
linkage for a common human disease: a Crohn disease susceptibility locus on chromosome 16 (maximum LOD
score 5.79). Despite failure to replicate the previous evidence for linkage on chromosome 12, the results described
herein indicate the need to further investigate the potential role of this locus in susceptibility to ulcerative colitis.
This report provides a convincing example of the collaborative approach necessary to obtain the sample numbers
required to achieve statistical power in studies of complex human traits.
Introduction
The idiopathic inflammatory bowel diseases (IBD)—
Crohn disease (CD) and ulcerative colitis (UC)—are
common complex genetic disorders with a combined
prevalence of ∼100–300/100,000 in developed coun-
tries. Both diseases involve an excessive inflammatory
reaction in the intestines, and symptoms include diar-
rhea, abdominal pain, and rectal bleeding. Both disor-
ders respond to similar drug therapies. CD can involve
any portion of the gastrointestinal tract and all layers
of the intestine. The inflammation is patchy and discon-
tinuous, with granulomas observed in some cases. In UC,
only the innermost layers of the intestinal wall are in-
volved, although the length of colon involved varies, but
the inflammation itself is diffuse and continuous. The
early steps in pathogenesis remain undefined in both
diseases.
It has been demonstrated that 5%–10% of patients
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have a first-degree relative who also has IBD (Binder
1998). Among families with more than one affected
individual, about 75%–80% are concordant for the
same disease within the pedigree and 20% are mixed
(having one member with UC and another with CD),
with Ashkenazi Jews having both higher disease prev-
alence and higher familial concordance for both diseases
(Binder 1998). Data from twin studies give support to
the distinction between the two diseases, with higher
concordance rates for monozygotic twins compared to
dizygotic twins for the same disorder, but low concor-
dance across disorders. The estimated ls is 15–30 for
CD and 8–10 for UC (Binder 1998; Yang and Rotter
1999). These data indicate a significant familial com-
ponent to pathogenesis in these chronic inflammatory
disorders.
Before the initiation of the current study, evidence for
linkage in two regions had been reported at genomewide
significance levels: the pericentromeric region on chro-
mosome 16 (IBD1 [MIM 266600]) (Hugot et al. 1996)
and chromosome 12q (IBD2 [MIM 601458]) (Satsangi
et al. 1996). Not all follow-up linkage studies, however,
replicated these findings (as indicated in tables 1 and
2). Significant differences appeared to exist between
these studies, in ethnic mix, numbers of families in each
disease type, and genetic markers used. To resolve these
differences, we undertook a multicenter linkage study
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Table 1
Evidence for Linkage to IBD1, Indicating Multipoint Linkage Scores, P Values, and MAS, for the Peak Location,
Recorded for Each Study
Multipoint
Score P Value MAS
No. of
Families
Disease
(CD/UC/Mixed) Marker Reference
3.17a .0004 .64 73 73/0/0 D16S409–D16S419 Hugot et al. (1996)
2.41 .019 .58 79 48/16/15 D16S411 Ohmen et al. (1996)
2.6 .002 … 186 81/64/41 D16S411 Parkes et al. (1996)
2.02 .02 … 70 0/32/38 D16S419 Mirza et al. (1998)
2.49 .007 … 77 77/0/0 D16S769 Brant et al. (1998)
6.3 .0000017 .72 73 54/0/19 D16S409 Cavanaugh et al. (1998)
1.71 .01 .56 274 129/90/50 D16S409–D16S411 Curran et al. (1998);
Hampe et al. (1999)
.25 … … 161 114/36/50 D16S753 Rioux et al. (1998)
2.71 … … 58 16/23/19 D16S408 Annese et al. (1999)
.69 .5 … 54 47/0/7 D16S411 Vermeire et al. (2000)
a The original study identifying the location.
of both regions by examining 613 families with at least
two offspring affected with IBD and for which DNA
was available from both parents, to critically assess
whether the two locations are indeed linked to IBD.
Subjects and Methods
We have studied, from 12 centers on three continents,
613 white nuclear families having two or more sibling
pairs with IBD and both parents available for genotyp-
ing. Families were chosen only on the basis of complete-
ness and not on prior knowledge of genotyping results.
None of these families were included in the original re-
port of linkage on chromosome 16 (Hugot et al. 1996),
although 68 families from the United Kingdom were
included in the linkage report for chromosome 12 (Sat-
sangi et al. 1996). We specifically excluded these 68 fam-
ilies from analysis of the chromosome 12 data. Families
were analyzed as either “pure CD,” “pure UC,” or, if
both diseases occurred in the nuclear family studied,
“mixed.” Jewish ethnicity was determined by the iden-
tification of two or more grandparents as Jewish. Fam-
ilies with both parents affected were excluded. All sites
used internationally accepted criteria for diagnosis of
IBD, all subjects gave written informed consent, and
each institution operated with the approval of the ap-
propriate institutional review board or ethics committee.
Each center genotyped all family members for six
markers surrounding each of the proposed localizations
for IBD1 on chromosome 16 and IBD2 on chromosome
12. We achieved 98% completion of genotyping. All
genotype and family data were anonymized prior to
deposition at the data coordinating center, so as to com-
ply with ethical requirements for removal of all iden-
tifiers prior to sharing of genotype information. Given
the full availability of parental genotypes, allele num-
bering was assigned sequentially within pedigrees prior
to data submission. The inclusion of all parents obviated
the need to estimate allele frequencies.
Individuals with records at more than one center were
identified by comparing birth date, gender records, and
pedigree structure at the central collection site. Individ-
uals thus identified were then compared by initials and
were validated by comparison of the first three letters
of their first and last names. Raw genotype data for
families with duplicate records were compared across
centers, and, where discrepancies occurred, genotypes
were repeated to obtain consensus or were set to “un-
known.” Ten North American families with duplicate
records were identified and were removed from center-
specific records. These families were included only once
in the analysis, as a separate North American data set.
Results for the 68 English families used in the original
description of the IBD2 locus on chromosome 12 were
excluded from the analyses for chromosome 12. Results
for chromosome 16 markers include all 99 English
families.
Nonparametric analyses were performed using Aspex
and GENEHUNTER 2.0 (Kruglyak et al. 1996), and
results were consistent across statistical programs. Both
single-point and multipoint maximum LOD scores
(MLSs) were derived at each of the marker loci and for
locations between markers. For families with more than
two sibs, all possible pairs were formed and included
in analysis. No weighting of families with multiple sib-
lings was used; in this case, any downweighting of fam-
ilies with multiple siblings resulted in a higher LOD
score, so this choice was conservative. Genotypes that
were likely erroneous (as a result of their introducing
double-crossovers in short intervals) were removed
prior to linkage analysis. After this procedure, the ge-
netic maps derived from the current data were more
consistent with published maps.
Heterogeneity tests betweenN groupswere calculated
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Table 2
Evidence for Linkage to IBD2, Indicating Multipoint Linkage Scores, P Values, and MAS, for the Peak
Location, Recorded for Each Study
Maximum
Multipoint
Score P Value MAS
No. of
Families
Disease
(CD/UC/Mixed) Marker Reference
5.47a .0000003 .65 160 67/60/33 D12S83 Satsangi et al. (1996)
.6 … … 77 77/0/0 D12S398 Brant et al. (1998)
1.6 .006 .55 274 134/90/50 D12S379–D12S388 Curran et al. (1998)
.30 .24 … 161 114/36/50 D12S1294 Rioux et al. (1998)
2.76 .00016 … 122 80/22/20 D12S1724–D12S90 Duerr et al. (1998)
2.0 .0004 .62 75 46/16/13 D12S85 Yang et al. (1999)
1.82 .0016 .61 268 129/90/49 D12S303–D12S326 Hampe et al. (1999)
.30 .39 … 54 47/0/7 D12S83 Vermeire et al. (2000)
a The original study identifying the location.
Table 3
Structure of Sample by Site, Indicating the Numbers of Families by
Site, Disease, Ethnicity, and Sibship Size
NO. OF FAMILIES
Total
Disease
(CD/UC/
Mixed)
Ethnicity
(Jewish/
Non-Jewish)
Sibship Size
(2/3/4/5)
Australia 53 36/ 4/ 13 2/ 51 47/ 6/0/0
Belgium 51 40/ 3/ 8 0/ 51 43/ 7/1/0
England:a
Group 1 68 37/ 19/ 12 0/ 99 64/ 4/0/0
Group 2 31 14/ 8/ 9 30/ 1/0/0
Total 99 51/ 27/ 21 94/ 5/0/0
Finland 41 10/ 18/ 13 0/ 41 36/ 4/1/0
Franceb 50 35/ 9/ 6 0/ 50 45/ 4/1/0
Italy 42 13/ 20/ 9 0/ 42 40/ 2/0/0
Baltimore 44 33/ 2/ 9 15/ 29 38/ 5/1/0
Chicago 46 28/ 4/ 14 19/ 27 43/ 2/1/0
Los Angeles 37 37/ 0/ 0 10/ 27 31/ 6/0/0
New York 29 27/ 0/ 2 19/ 10 25/ 4/0/0
Pittsburgh 63 38/ 10/ 15 12/ 51 53/ 8/1/1
Toronto 48 30/ 11/ 7 11/ 37 46/ 2/0/0
North Americac 10 9/ 0/ 1 4/ 6 8/ 2/0/0
Total 613 386/108/119 92/521 549/57/6/1
a Sixty-eight families used in this study (group 1) were used else-
where to detect IBD2.
b None of the families used to detect IBD1 were used in this study.
c Families were studied by two or more groups.
as , where S(MLS1) is theUp 4.606[S(MLS1)–MLS2]
summed MLS across groups at the given map location
and MLS2 is the MLS for all groups pooled. Under the
null hypothesis of no heterogeneity, U has a x2 distri-
bution with df.N 1
Results
Twelve groups contributed families from North Amer-
ica, Europe, and Australia. All families were white. Table
3 shows the number of families by center, along with
disease, ethnicity (Jewish/non-Jewish), and sibship size.
The percentage of families with one affected parent was
consistent across sites, at ∼10%. For the purpose of com-
parison, the mean allele sharing (MAS) at all markers
on chromosomes 12 and 16 was computed by individual
center (table 4) as well as in total.
Multipoint analysis was undertaken on the combined
data set and demonstrated strong evidence of linkage
to multiple markers on chromosome 16 (table 5). A
peak LOD score of 4.96 was seen between markers
D16S411 and D16S419 (fig. 1). When the analysis was
restricted to the families with CD only, an MLS of 5.79
was observed in the same interval (fig. 1). In contrast,
both the pure UC and the mixed families showed no
evidence for linkage in this region of chromosome 16.
A test of heterogeneity among these three diagnostic
groups at the peak multipoint marker (D16S411) is
close to significant ( , , ). When2x p 5.39 dfp 2 Pp .06
the multipoint curves for the three diagnostic groups
are examined, it is clear that IBD1 is almost certainly
a uniquely CD locus.
A second heterogeneity analysis, designed to examine
whether any centers contributed disproportionately to
the linkage evidence at IBD1, was performed using the
linkage data at the peak marker (D16S411). This test
demonstrated that there was no statistical evidence for
heterogeneity between centers, either for the whole set
of IBD families ( , , ) or for2x p 10.69 dfp 12 P 1 .50
the subset of families with CD only ( ,2x p 14.05
, ). Furthermore, it is clear that the highdfp 12 Pp .30
total MLS is obtained only through combination of re-
sults from all centers, since no individual center dom-
inates the linkage evidence (multipoint MLS by center
for all IBD is 1.75 [Baltimore] and for CD only is 1.50
[Finland]). Examination of the LOD scores by individ-
ual centers reveals no striking linkage evidence, and only
the pooled LOD score is remarkable.
Having conclusively confirmed IBD1, we performed
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Table 4
Results of Two-Point Nonparametric Analyses by Site, Indicating MAS
SITE
FREQUENCY
D12S85 D12S368 D12S90 D12S83 D12S313 D12S326 D16S403 D16S753 D16S409 D16S411 D16S419 D16S408
Australia
(n p 53)
.47 .55 .62 .51 .55 .55 .59 .64 .64 .56 .61 .57
Belgium
(n p 51)
.60 .45 .39 .47 .48 .42 .52 .56 .49 .58 .60 .58
England:a
Group 1
(n p 31)
.53 .39 .38 .39 .53 .54
Total
(np 99)
.52 .53 .52 .53 .49 .54
Finland
(n p 41)
.59 .59 .50 .46 .54 .49 .54 .57 .65 .63 .58 .57
France
(n p 50)
.49 .54 .51 .49 .50 .49 .63 .58 .56 .60 .65 .60
Italy
(n p 42)
.60 .55 .54 .52 .59 .63 .51 .49 .47 .47 .67 .73
Baltimore
(n p 44)
.51 .49 .47 .47 .48 .43 .61 .56 .55 .64 .51 .55
Chicago
(n p 46)
.48 .54 .45 .52 .52 .52 .48 .54 .52 .51 .51 .50
Los Angeles
(n p 37)
.58 .59 .53 .56 .49 .54 .53 .51 .53 .55 .47 .44
New York
(n p 29)
.48 .56 .60 .53 .54 .50 .52 .59 .54 .51 .55 .55
Pittsburgh
(n p 63)
.63 .55 .54 .57 .50 .50 .52 .52 .53 .53 .58 .56
Toronto
(n p 48)
.53 .54 .58 .51 .55 .54 .50 .57 .60 .58 .53 .44
North Americab
(n p 10)
.74 .55 .52 .50 .45 .47 .58 .39 .46 .41 .38 .41
Overall
(n p 613)
.55 .53 .51 .50 .52 .51 .54 .55 .55 .55 .56 .55
a Sixty-eight families used in the original description of the IBD2 localization were excluded from the analysis of chromosome 12 markers
but were included in the analysis of chromosome 16 markers.
b Families were studied by two or more groups.
additional analysis to elucidate the action of this locus.
We examined, separately, Jewish and non-Jewish fam-
ilies with CD only. There was little difference in allele
sharing between these two groups (59% vs. 58% for
Jewish vs. non-Jewish, respectively, at D16S409). We
also examined allele sharing in two groups of families
with CD only: (1) families with a single affected sib pair
(ASP), and (2) families with three or more affected sibs
(dense families). The excess allele sharing on chromo-
some 16 was confined to families of group 1 (1 ASP
only), with an observed multipoint allele sharing of
60.7% at D16S411 and an MLS of 6.51 (total of 338
ASPs). By contrast, in the denser families of group 2,
the allele sharing at the same marker was only 52.8%
and the MLSp 0.22 (total of 166 ASPs). The difference
in allele sharing between groups 1 and 2 is statistically
significant (x , , ).2p 4.88 dfp 1 P ! .05
The level of support for linkage for the IBD2 locus
on chromosome 12 is considerably weaker (see table
5). When multipoint analysis was performed, a maxi-
mum multipoint LOD score of 1.2 ( atMASp .53
D12S368) was obtained for all disease types combined.
The strongest evidence for linkage at IBD2 is in the
families with UC, since the largest amount of allele shar-
ing for any marker in this study is seen in families with
UC at D12S85 (59%).
Discussion
We have shown that the localization for IBD1 on chro-
mosome 16 is a pure CD locus, and with an MLS of
5.79 in these families, we demonstrate the most com-
pelling statistical evidence to date for a novel genetic
localization in complex disease mapping.
The lack of linkage evidence to IBD1 in the dense
families with CD is an intriguing finding. This obser-
vation may be a consequence of a second rare disease
locus segregating in the dense families. Alternatively, we
believe that this phenomenon could be a consequence
of a high disease-allele frequency on chromosome 16,
IBD International Genetics Consortium: Crohn Disease on Chromosome 16 1169
Table 5
Multipoint MAS and MLS Results by Disease Type
PURE CD PURE UC MIXEDa ALL IBD
MARKER MAS MLS MAS MLS MAS MLS MAS MLS
n p 349 n p 89 n p 107 n p 545
D12S85 .53 .5 .59 1.2 .52 .0 .53 1.1
D12S368 .53 .7 .56 .6 .52 .1 .53 1.2
D12S90 .53 .6 .53 .1 .49 .0 .52 .5
D12S83 .53 .7 .49 .0 .48 .0 .52 .3
D12S313 .52 .3 .52 .0 .49 .0 .51 .2
D12S326 .51 .1 .57 .8 .49 .0 .52 .3
n p 386 n p 108 n p 119 n p 613
D16S403 .55 1.7 .48 .0 .53 .2 .54 1.4
D16S753 .57 3.8 .51 .0 .52 .1 .55 3.2
D16S409 .58 5.0 .50 .0 .52 .1 .55 3.8
D16S411 .58 5.7 .51 .0 .54 .3 .55 4.9
D16S419 .58 4.8 .50 .0 .53 .2 .56 3.9
D16S408 .57 3.3 .51 .0 .56 .5 .55 3.4
a Mixed families are those in which any two first-degree relatives
who are affected have different forms of disease.
Figure 1 Multipoint LOD score on chromosome 16 by disease
group—CD, UC, and mixed—and for all IBD.
leading to high levels of disease-allele homozygosity in
the population (whether or not such individuals develop
disease). Maximizing over models by parametric linkage
analyses of these data indicates that the disease-allele
frequency may be as high as .35 (data not shown). It
is likely that parents who are homozygous for the dis-
ease allele would be overrepresented in denser families
compared with families having two affected sibs (Rotter
1981). In such families, the ability to detect linkage
between the disease and marker locus is reduced, be-
cause the disease allele is transmitted with both parental
marker alleles. These families will therefore show re-
duced evidence for linkage. This is not a consequence
of loss of information at the marker loci, since, in our
data, there is no evidence for excess parental homozy-
gosity in any of the microsatellite markers studied when
the dense families are compared to families with two
affected siblings (data not shown). These observations
concerning the dense families have important implica-
tions for study design in complex disease analyses, par-
ticularly when disease-allele frequencies are high. In
such situations, it would be wise to analyze different
types of family structures separately, to detect results
such as those reported here.
On the other hand, the support for linkage to IBD2
is reduced in this sample but is still slightly suggestive,
given that this was a replication study. It is possible that
this localization is more important for susceptibility to
UC than to CD, although far fewer families with UC
than with CD were studied. This suggestion has been
supported recently by a study by Parkes et al. (2000),
using 138 relative pairs affected with UC, in which they
showed that IBD2 appears to make a major contribu-
tion to susceptibility to UC but to have only a relatively
minor effect on susceptibility to CD.
Positional cloning approaches to the identification of
disease genes through linkage studies were originally
developed for monogenic disorders. Adopting this ap-
proach for the identification of susceptibility genes for
complex disorders, however, has remained largely un-
successful. Specifically, such studies have frequently
been hampered by failure to replicate linkage findings
(Bell and Lathrop 1996; Concannon et al. 1998). Fur-
thermore, most significant results in genetic studies of
complex diseases come from the use of the candidate-
locus approach (identification of the MHC complex in
IDDM susceptibility) rather than from a systematic link-
age approach. It is reasonable, however, to expect that
many susceptibility genes for complex disorders will
probably be loci of modest effect, and, as a consequence,
difficulties in localization and nonreplication may result
from limitations of power. The results of the present
study clearly indicate that, at least in this case, the large
number of families necessary for sufficient statistical
power could be obtained in the context of a large col-
laborative effort. This is therefore the first complex hu-
man disease for which a truly novel locus, IBD1, iden-
tified initially by genomewide linkage studies, has been
unequivocally confirmed by a large international col-
laboration. With these results, studies to identify this
gene can now be developed.
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